Paying For Obesity Drugs: The Looming Affordability Crisis

As use of new obesity medicines become more widespread, experts at the J.P. Morgan Healthcare conference predicted that paying for them will stress state governments and employers.

money on a scale
Paying for new obesity drugs will be a costly proposition • Source: Shutterstock

Despite the unbridled enthusiasm for new obesity drugs, which are expected to drive pharmaceutical sector growth along with delivering weight loss and related health benefits to patients, paying for the long-term use of the chronic treatments in widespread patient populations is going to present an affordability crisis, experts said at the J.P. Morgan Healthcare Conference.

Key Takeaways

  • Experts at the J.P. Morgan Healthcare Conference discussed the high cost of paying for new obesity drugs and challenges to market access.

Obesity was a big theme throughout the meeting, held in San Francisco from 8 to 11 January, with nearly every...

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Market Access

More from Pink Sheet